Beyond Air Appoints Robert Goodman as CEO to Drive LungFit PH Expansion
Beyond Air CEO Steve Lisi will resign effective March 27, 2026, and CCO Robert Goodman will assume the role immediately to accelerate LungFit PH market adoption and scale international and U.S. commercial operations. Goodman brings over two decades of medtech and pharmaceutical leadership, including roles at Philips Healthcare and Thermo Fisher.
1. Leadership Transition Details
On March 26, 2026, Beyond Air announced that CEO Steve Lisi will resign effective March 27 and step down from the board to pursue other opportunities. The board appointed Robert Goodman, the current Chief Commercial Officer and director, as CEO, ensuring a seamless transition with no expected operational disruption.
2. Incoming CEO Robert Goodman
Goodman served as Chief Commercial Officer since November 2025 and joined the board in June 2025, leading a rapid business strategy overhaul focused on technology, process and people. He brings over twenty years of leadership in medical technology and pharmaceutical firms, including roles at Philips Healthcare, Thermo Fisher Scientific and Pfizer.
3. Commercial Growth Strategy
Goodman aims to accelerate LungFit PH adoption in U.S. and international markets by sharpening commercial execution and strengthening customer partnerships. The company plans to leverage Goodman’s global expansion expertise to scale operations and unlock the long-term potential of its inhaled nitric oxide platform.